Zydus Cadila has received the final approval from the USFDA to market Zolmitriptan Tablets, 2.5 mg and 5 mg. It is used to treat migraines. It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting and sensitivity to light/sound). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

In line with this, the group now has 203 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 2.55, or 0.69%, to trade at Rs 368.95. The total volume of shares traded was 37,256 at the BSE (10.24 a.m., Thursday).